were used as denominators in the calculation of incremental CE ratios (ICER) are decreased frequencies of mild hypoxia, severe hypoxia and pneumonia. RESULTS: Frequencies of residual NMB were estimated as 51.2% 44.6% and 0.4% in SR, neostigmine and Bridion groups, respectively. Hypoxia rate was calculated as 27.4% and 11.4% in patients with and without residual NMB. Frequencies of pneumonia were 17.2% and 5.9% in patients with and without residual NMB. Percentage of patients without any complication was found to be 88.0% in Bridion group, while it was 73.8% and 75.7% in SR and neostigmine groups. The costs of complications were 126. 45 c and 114. 56 c in SR and neostigmine groups, while it was only 34. 93 c in Bridion® group. When medication cost was added, the total cost rose to 114. 62 c in Bridion® group, which was still lower than the total costs of SR and neostigmine groups. The rate of severe hypoxia was estimated as 7.9% in Bridion® group, while it was 13.5% and 12.7% in SR and neostigmine groups, respectively. Pneumonia was seen in 1.2% of the patients in Bridion® group, while the frequencies of pneumonia were 9.4% and 8.3% in SR and neostigmine groups. CONCLUSIONS: Bridion® was found to be dominant to both SR and neostigmine groups, in terms of decrease in frequencies of hypoxia and pulmonary complications. OBJECTIVES: To conduct pharmacoeconomic evaluation of Levodopa/Carbidopa/ Entacapone (LCE) compared to standard therapy in Parkinson disease treatment. Standard therapy was presented by Levodopa and Carbidopa. METHODS: The costeffectiveness study was carried conducted. Effectiveness was measured in DALYs. Time horizont for cost-effectiveness analysis was 2 years. a 3% discount rate was used. 1 EUR = 40 RUB. RESULTS: LCE provided benefi ts in effectiveness compared to standard therapy. LCE reduced days incapacity index twice from 44 to 21 days. Two year pilot study showed that LCE provided 0,83 DALY, than standard therapy presented 0,5 DALY. Also administration of LCE reduced daily Levodopa dose on 68 mg. Total annual costs for LCE therapy were 158 938 (3 974 EUR) RUB. Standard therapy total costs varied from 129 113 RUB (3 228 EUR) to 145 422 RUB (3 636 EUR) yearly according to disease progression grade. Indirect costs, including GDP losses due to temporary disability and payments for temporary disability, were 14 372 RUB (359 EUR) for LCE and 30 113 RUB (753 EUR) for standard therapy. The costeffectiveness ratio for LCE was 191 492 RUB (4 787 EUR) per DALY, than for standard therapy it was 258 326 RUB (6 458 EUR) per DALY. CONCLUSIONS: LCE demonstrates lower cost-effectiveness ratio (191 492 RUB) compared to standard Parkinson disease therapy (258 326 RUB), therefore LCE has an advantage over standard therapy in terms of pharmacoeconomic evaluation.
PND24 THE IMPACT OF COHORT SELECTION ON COST-EFFECTIVENESS RESULTS IN MULTIPLE SCLEROSIS
Becker RV 1 , Dembek C 2 1 Russell Becker Consulting, Chicago, IL, USA; 2 Biogen Idec GmbH, Wellesley, MA, USA OBJECTIVES: Adherence to cost-effectiveness analytic guidelines requires careful assessment of clinical trial results to ensure the most appropriate cohort data selection. This study examines the impact of cohort selection on the results of the Goldberg, et al. 2009 cost-effectiveness study of disease-modifying therapies (DMTs) in multiple sclerosis (MS) . METHODS: Using intent-to-treat (ITT) two-year data from pivotal trials, Goldberg compared cost per relapse avoided of fi rst-line DMTs. However, there are important differences in the ITT cohorts among the trials. Due to lower than expected subject drop-out rates, the interferon beta-1a IM (INF-b-1a-IM) trial was able to meet its primary endpoint with a reduced sample size and a decision was made to terminate the trial early. This resulted in almost half of the 301 ITT (or "allpatient") cohort being on study drug for less than two years. a second, "two-year" 172 patient cohort consisted of patients who had completed two years on drug therapy. Goldberg used the INF-b-1a-IM "all-patient" cohort in his cost study. To test the impact of this cohort selection, we recreated Goldberg's model using the "allpatient" relapse rate (0.67 for INF-b-1a-IM vs. 0.82 for placebo) and then substituted the "two-year" cohort data (relapse rate of 0.61 for INF-b-1a-IM vs. 0.90 for placebo) and compared results. RESULTS: This study's cost per relapse avoided was 45% lower for INF-b-1a-IM while the results for the other DMTs were comparable to those reported by Goldberg. Ranked from most to least cost-effective, the model results were $77,980 for INF-b-1a-IM, $80,121 for interferon beta-1a SC, $86,572 for interferon beta-1b, and $87,767 for glatiramer. CONCLUSIONS: Our analysis demonstrates the importance of cohort selection in cost-effectiveness analyses in MS. By selecting comparable cohort data from patients who had completed at least two years on study drug, we found that INF-b-1a-IM had the lowest cost per relapse avoided of all fi rstline DMTs.
PND25 ECONOMIC EVALUATION OF NATALIZUMAB IN THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN 4 EUROPEAN COUNTRIES
Brennig C, Walter E, Schöllbauer V Institute for Pharmaeconomic Research, Vienna, Austria OBJECTIVES: Multiple sclerosis (MS) is an infl ammatory, neurodegenerative condition of central nervous system with prevalence of 1 Million worldwide (age at fi rst manifestation 20-40 years). MS may lead to permanent disability and early retirement even in young adults. The purpose of this analysis was to provide an economic assessment of relapsing-remitting MS-treatment with Natalizumab versus Interferons and Copolymer in 4 European countries (Austria, Czech Republic, Slovakia, Slovenia). METHODS: The analysis was performed using a Markov model. The model allows a treatment switch due to relapse. Effi cacy assessment was based on the outcome measure "relapse-free patients". Costs were captured for the year 2010. Resource use was determined from results of a survey conducted by the Austrian MS Society and accurately refl ects the therapeutic approach. Resource use of Czech Republic, Slovakia and Slovenia was determined via country-specifi c research. Where country specifi c data could not be captured, Austrian data was adjusted via Purchasing Power Parities (PPP). The study time horizon was 2 years. The analysis was performed from the perspective of the health care system of the 4 European countries. RESULTS: In Czech Republic the average cost of the therapy algorithm Natalizumab amount to c33,835 per patient within the time horizon of 2 years versus c22,896 (Interferon) and c21,256 (Copolymer). a patient successfully treated with Natalizumab accounts for c56,525 compared to c70,190 (Interferon) and for c87,555 (Copolymer). In Slovakia a relapsefree patient values c60,357 (Natalizumab) versus c58,043 (Interferon) and c19,921 (Copolymer). a relapse-free patient in Slovenia values c59,108 (Natalizumab) versus c66,202 (Interferon) and c84,207 (Copolymer). In Austria a relapse-free patient values c58,423 (Natalizumab) versus c71,906 (Interferon) and c89,591 (Copolymer). CON-CLUSIONS: In Czech Republic, Slovenia, and Austria, treatment of MS with Natalizumab is more cost-effective than Interferon resp. Copolymer 1 therapy. Switching to effective and more expensive alternatives does not account for higher health care costs.
PND26

MEDICO-ECONOMIC EVALUATION OF LACOSAMIDE ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH REFRACTORY EPILEPSY IN SCOTLAND AND SPAIN
Benhaddi H 1 , Gunn A 1 , Ferro B 2 1 UCB Pharma S.A., Brussels, Belgium; 2 UCB Pharma S.A., Madrid, Spain OBJECTIVES: To calculate and compare the incremental cost-utility ratios for standard antiepileptic drug (AED) therapy with and without adjunctive lacosamide in patients with uncontrolled partial-onset seizures. METHODS: The model simulated the treatment pathway of a hypothetical cohort of 1000 patients over 2 years from the perspectives of the National Health Service (NHS) in Scotland and the Spanish Healthcare System (SNS) in 2008. a decision tree was split into four phases of six months each during which patients can become seizure free, experience a seizure reduction (responder defi ned as ≥50% reduction in seizures), or withdraw due to non-response. The standard therapy arm included carbamazepine, lamotrigine, levetiracetam, topiramate, and valproate. The likelihood of being in a particular health state has been estimated from clinical data. The cost of general practitioner visits, outpatient visits, hospitalizations and emergency department visits were included. Costs and utility values attached to various health states were taken from the published literature. RESULTS: Lacosamide adjunctive therapy was associated with 6730 avoided seizures and a gain of 38 quality adjusted life-years (QALYs), compared to the standard therapy arm within the two-year timeframe. Treatment with lacosamide was associated with a cost of £113 and c107 per seizure avoided, and £20,017 and c22,771 per QALY gained versus standard therapy in Scotland and Spain, respectively. Results calculated for 6-, 12-and 18-month follow-up showed respective incremental cost-utility ratios of £23, 479, £21, 422 and £20, 998 in Scotland, and c23, 771, c20, 703 and c21, 778 in Spain. Using a willingness-to-pay threshold of £30,000 per QALY, 80% of the simulations in Scotland and 74.2% in Spain fell below this value after 2 years of treatment. CONCLUSIONS: Lacosamide was shown to be a cost-effective adjunctive treatment in patients with uncontrolled partial-onset epilepsy in Scotland and Spain.
PND27 COST UTILITY ANALYSIS OF ORPHAN DRUGS: CASE STUDY OF DUODENAL LEVODOPA INFUSION VERSUS STANDARD TREATMENT IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE IN SWEDEN
Willis M 1 , Gradl B 2 1 IHE, Lund, Sweden; 2 Abbott Products Operations AG, Allschwil, Switzerland BACKGROUND: Advanced Parkinson's disease (APD) severely impacts the quality of life (QoL) for both patients and their caregiver and is associated with high health care and societal costs. The treatment options for those patients are limited. Duodenal levodopa infusion (DLI), an orphan drug, has shown to restore symptom control and to improve QoL substantially for both patients and their carers. OBJECTIVES: To evaluate the cost-utility of DLI versus standard treatment (including oral treatment and subcutaneous dopamine agonists) in patients with advanced PD in Sweden. METHODS: A stochastic Markov-based simulation model was developed. Health was described by 12 health states refl ecting 4 categories of "OFF" time and 3 severity stages as measured by the Hoehn & Yahr scale. The clinical effect for both treatment arms was derived from published clinical trials; costs and QoL utilities were taken from an interim analysis of the ongoing DAPHNE study. The base case simulated 5 years with costs/effects discounted by 3%. The societal perspective was adopted. RESULTS: The model estimated an improvement from 0.68 to 1.30 QALYs and a cost increase from 1,410,643 (c147,108) to SEK 1, 674, 295 (c174, 603) for DLI versus standard treatment, leading to an incremental cost-effectiveness ratio (ICER) of around SEK 420,000 (c43,800) per QALY gained. The ICER for nearly 90% of the cohorts fell below SEK 655,000 (c68,306), the willingness-to-pay threshold often cited
